Citigroup Inc Cyma Bay Therapeutics, Inc. Call Options Transaction History

Citigroup Inc

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 09, 2024	BUY	$12.63 - $24.47 $378,900 - $734,100	30,000 New	30,000 $708,000
Q1 2023 May 11, 2023	BUY	$5.88 - $9.59 $441,000 - $719,250	75,000 Added 93.75%	155,000 $1.35 Million
Q4 2022 Feb 09, 2023	BUY	$3.22 - $6.27 $112,700 - $219,449	35,000 Added 77.78%	80,000 $501,000
Q3 2022 Nov 10, 2022	BUY	$2.77 - $4.25 $124,650 - $191,250	45,000 New	45,000 $158,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.